HRS-4508 + capecitabine

HRS-4508 + capecitabine is an investigational combination therapy comprising the small molecule HRS-4508 and the cytotoxic agent capecitabine. HRS-4508 is a chemical drug developed by Jiangsu Hengrui Pharmaceuticals for the potential treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC). Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), routinely used in chemotherapy. Early-phase clinical trials are evaluating this combination’s safety, pharmacokinetics, and anti-tumor efficacy endpoints such as objective response rate, duration of response, progression-free survival, and overall survival in solid tumors, notably NSCLC. The exact molecular target and mechanism of HRS-4508 have not been publicly disclosed as of June 2025, but ongoing studies are monitoring blood concentrations and combination effects[4][7].